ALK and non-small cell lung carcinoma: Although several ALK-targeted tyrosine kinase inhibitors (TKIs) have been approved for patients with ALK-positive (ALK+) NSCLC, achieving complete regression is rare due to the development of resistance to these ALK TKIs.